1. Clinical & Scientific Overview
Ciprofloxacin Hydrochloride (TIP-MED-000136, Reference Code [8.8]) is classified under
Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08) as a Second-Generation Fluoroquinolone Antibiotic (Bactericidal DNA Gyrase & Topoisomerase IV Inhibitor; WHO 'Watch' Group).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug • NLEM 2022 Core Essential Medicine.
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.8], p. 96): Ciplox (Cipla), Ciprobid (Zydus), Cifran (Sun Pharma), Alcipro (Alkem); Extended-Release: Cifran-OD (500 mg, 1000 mg) — Strengths & Forms: Oral Film-Coated Tablets: 250 mg, 500 mg, 750 mg; Extended-Release Tablets: 500 mg OD, 1000 mg OD; IV Infusion: 200 mg/100 mL; Ophthalmic/Otic Drops: 0.3% w/v
Oral Film-Coated Tablets: 250 mg, 500 mg, 750 mg; Extended-Release Tablets: 500 mg OD, 1000 mg OD; IV Infusion: 200 mg/100 mL; Ophthalmic/Otic Drops: 0.3% w/v
3. Mechanism of Action & Pharmacodynamics
Enters bacteria via outer-membrane porins and traps bacterial type II topoisomerases — primarily DNA Gyrase (GyrA/GyrB — primary target in Gram-negative bacilli, preventing negative supercoiling relaxation ahead of the replication fork) and Topoisomerase IV (ParC/ParE — primary target in Gram-positive cocci, preventing daughter chromosome decatenation) — forming ternary drug-enzyme-DNA cleavage complexes that trigger rapid concentration-dependent bactericidal cell death (fAUC24/MIC >= 125; Cmax/MIC >= 10).
4. Therapeutic Indications & Evidence-Supported Uses
- Complicated urinary tract infections, acute pyelonephritis, and chronic bacterial prostatitis
- Infectious bacterial gastroenteritis (shigellosis, cholera, invasive salmonellosis where susceptible) and Pseudomonas aeruginosa infections
- Anthrax post-exposure prophylaxis and meningococcal chemoprophylaxis
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adults: 250–750 mg orally every 12 hours, or 400 mg IV infusion over 60 minutes every 8–12 hours.
Administration & Meal Timing: Oral (with water, away from dairy/antacids) or IV infusion over 60 minutes.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
No adjustment required unless combined with severe renal failure.
Reduce dose by 50% or extend interval to q18–24h when CrCl < 30 mL/min.
No adjustment required unless combined with severe renal failure.
7. Contraindications, Precautions & High-Risk Warnings
- Myasthenia gravis (blocks neuromuscular transmission and can precipitate fatal respiratory muscle weakness)
- History of fluoroquinolone-associated tendinitis or tendon rupture
- Concomitant Tizanidine (Ciprofloxacin inhibits CYP1A2 and increases Tizanidine AUC by 10-fold, causing profound hypotension and sedation!)
Key Clinical Precautions: No adjustment required unless combined with severe renal failure.
8. Adverse Effects Profile
- Tendinitis and spontaneous Achilles tendon rupture (mediated by matrix metalloproteinase upregulation and collagen degradation — highest risk in >60 yr, renal failure, or corticosteroid use)
- Peripheral neuropathy, CNS excitation (insomnia, dizziness, lowered seizure threshold via GABA-A antagonism, especially if combined with NSAIDs)
- QTc prolongation and aortic aneurysm/dissection risk in high-risk vascular patients
- Arthropathy in weight-bearing cartilage of immature animals
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Antacids (Al/Mg), Calcium, Iron, Zinc, Sucralfate, & Dairy products (milk/curd): chelate the 3-carboxyl-4-keto group of Ciprofloxacin and reduce bioavailability by up to 90% — take Ciprofloxacin 2 hours before or 6 hours after cations
- Theophylline, Tizanidine, Clozapine, Duloxetine, Caffeine, & R-Warfarin: Ciprofloxacin potently inhibits CYP1A2, precipitating Theophylline seizures/arrhythmias and Tizanidine collapse
- Corticosteroids: markedly increases risk of Achilles tendonitis and tendon rupture (especially in patients aged >60 yr)
- QT-prolonging drugs & Sulfonylureas: additive QTc prolongation and dysglycaemia
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Do NOT take Ciprofloxacin with milk, curd/yogurt, calcium tablets, iron supplements, or antacids — take with plain water at least 2 hours before or 6 hours after any mineral or dairy product.
- Stop taking immediately and rest the limb if pain, swelling, or inflammation develops in the Achilles tendon or ankle.
- Do not use empirically for suspected Tuberculosis (delays TB diagnosis and breeds fluoroquinolone-resistant MDR-TB).
Storage, Stability & Dispensing Safeguards: Store below 30°C protected from light.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2026) • NLEM 2022 (MoHFW) • CDSCO Approved Prescribing Information
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [8.23] Amikacin Sulfate & Gentamicin Sulfate — Aminoglycoside 30S Ribosomal Bactericidal Antibiotics (Schedule H
- [8.24] Moxifloxacin & Ofloxacin — Fourth- & Second-Generation Fluoroquinolone DNA Gyrase / Topoisom
- [8.25] Co-trimoxazole (Trimethoprim + Sulfamethoxazole — TMP-SMX) — Synergistic Sequential Folate Pathway Inhibitor — DHFR + DHPS Blo
- [8.26] Fosfomycin Trometamol — Phosphonic Acid Epoxide Cell-Wall (MurA) Synthesis Inhibitor — Si